BRIEF

on Moderna, Inc. (NASDAQ:MRNA)

Moderna Secures EU Tender for mRNA COVID-19 Vaccine Supply

Stock price chart of Moderna, Inc. (EBR:MRNA) showing fluctuations.

Moderna has announced it won a tender to supply its mRNA COVID-19 vaccine in the European Union, Norway, and North Macedonia. The agreement allows 17 countries to access the vaccine for up to four years, providing opportunities to diversify their supply. The inclusion of pre-filled syringes aims to improve vaccination efficiency by reducing administration errors and saving time.

In September 2024, the European Commission approved a new version of Moderna's Spikevax, targeting the SARS-CoV-2 variant JN.1. This formulation is suitable for individuals aged six months and older. The deal highlights Moderna's commitment to enhancing vaccination campaigns and health security.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Moderna, Inc. news